The effect of selective cyclooxygenase-2 inhibitor on human osteoclast precursors to influence osteoclastogenesis in vitro

Modern Rheumatology

Volumn 19, Issue 2, 2009, Pages 192-198

  Kawashima, Masayuki ^a   Fujikawa, Yosuke ^a   Itonaga, Ichiro ^a   Takita, Chikahiro ^a   Tsumura, Hiroshi ^a  

^a OITA UNIVERSITY   (Japan)

Author keywords

Celecoxib; COX 2; NSAIDs; Osteoclast

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; CELECOXIB; COLONY STIMULATING FACTOR 1; INDOMETACIN; MOFEZOLAC; NONSTEROID ANTIINFLAMMATORY AGENT; OSTEOCLAST DIFFERENTIATION FACTOR; PROSTAGLANDIN E2;

ARTICLE; BONE REGENERATION; CELL DIFFERENTIATION; CELL VIABILITY; CONTROLLED STUDY; DRUG MECHANISM; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; IN VITRO STUDY; MULTINUCLEAR CELL; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BONE RESORPTION; CELL GROWTH PROCESSES; CELL SURVIVAL; CELLS, CULTURED; CYCLOOXYGENASE 2 INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INDOMETHACIN; ISOXAZOLES; MACROPHAGE COLONY-STIMULATING FACTOR; OSTEOCLASTS; PYRAZOLES; RANK LIGAND; STEM CELLS; SULFONAMIDES; TIME FACTORS;

EID: 64449085731     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-008-0149-6     Document Type: Article

References (36)

1. Feyen JHM, van der Wilt G, Moonen P, et al. Stimulation of arachidonic acid metabolism in primary cultures of osteoblast-like cells by hormones and drug. Prostaglandins. 1984;28:213-20.
2. Harrison JR, Lorenzo JA, Kawaguchi H, et al. Stimulation of prostaglandin E2 production by interleukin-1α and transforming growth factor α in osteoblastic MC3T3-E1 cells. J Bone Miner Res. 1994;9:817-23.
3. Rodan SB, Rodan GA, Simmons HA, et al. Bone resorptive factor produced by osteosarcoma cells with osteoblastic features is PG E2. Biochem Biophys Res Common. 1981;102:1358-65.
4. Fletcher BS, Kujubu DA, Perrin DM, et al. Structure of the mitogen-inducible TIS10 gene and demonstration that TIS10-encoded protein is a functional prostaglandin G/H synthase. J Biol Chem. 1992;267:4338-44.
5. Kujubu DA, Fletcher BS, Varnum BC. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cell, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem. 1991;266:12866-72.
6. Vane J. Towards a better aspirin. Nature. 1994;367:215-6.
7. Xie WL, Chipman JG, Robertson DL, et al. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA. 1991;88:2692-6.
8. Khanna IK, Weier RM, Yu Y. 1, 2-Diarylimidazoles as potent and selective inhibitors of cyclooxygenase-2. J Med Chem. 1997;40:1619-33.
9. Khanna IK, Weier RM, Yu Y, et al. 1, 2-Diarylimidazoles as potent, cyclooxygenase-2 selective, and orally active anti-inflammatory agents. J Med Chem. 1997;40:1634-47.
10. Penning TD, Talley JJ, Bertenshaw SR, et al. Synthesis and biological evaluation of the 1, 5-diarylpyrazole class of cyclooxygenase-2 inhibitors: Identification of 4-[5-(4-methylphenyl)-3-trifluoromethyl-1H-pyrazol-1-yl]benzene sulfonamide (SC-58635, celecoxib). J Med Chem. 1997;40:1347-65.
11. Zhang Y, Shaffer A, Portanova J, et al. Inhibition of cyclooxygenase-2 rapidly reverses inflammatory hyperalgesia and prostaglandin E2 production. J Pharmacol Exp Ther. 1997;283:1069-75.
12. Lanza FI, Rack MF, Callison DA. A pilot endoscopic study of the gastroduodenal effects of SC-58635, a novel COX-2 selective inhibitor. Gastroenterology. 1997;112:194.
13. Simon LS, Lanza FL, Lipsky PE, et al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase-2 inhibitor: Efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum. 1998;41:1591-602.
14. Simon LS, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: A randomized control trial. JAMA. 1999;282:1921-8.
15. Zhao SZ, Hatoum HT, Hubbard RC, et al. Effect of celecoxib, a novel COX-2 inhibitor, on health-related quality of life patients with osteoarthritis of the knee. Arthritis Rheum. 1997;40:S88.
16. Geis GS, Hubbard RC, Callison D, et al. Safety and efficacy of celecoxib, a specific COX-2 inhibitor, in patients with rheumatoid arthritis. Arthritis Rheum. 1998;41:S364.
17. Hubbard RC, Koepp RJ, Yu S. SC-58635 (celecoxib), a novel COX-2 selective inhibitor, is effective as a treatment for osteoarthritis (OA) in a short-term pilot study. Arthritis Rheum. 1996;39:S226.
18. Hubbard RC, Geis GS, Woods E, et al. Efficacy, tolerability, and safety of celecoxib, a specific COX-2 inhibitor, in osteoarthritis. Arthritis Rheum. 1998;41:S196.
19. Igarashi K, Woo JT, Stern PH. Effects of a selective cyclooxygenase-2 inhibitor, celecoxib, on bone resorption and osteoclastgenesis in vitro. Biochem Pharmacol. 2002;63:523-32.
20. Im GI, Kwon BC, Lee KB. The effect of COX-2 inhibitors on periprosthetic osteolysis. Biomaterials. 2004;25:269-75.
21. Ono K, Akatsu T, Murakami T, et al. Involvement of cyclo-oxygenase-2 in osteoclast formation and bone destruction in bone metastasis of mammary carcinoma cell lines. J Bone Miner Res. 2002;17:774-81.
22. Zhang X, Morham SG, Langenbach R, et al. Evidence for a direct role of cyclo-oxygenase 2 in implant wear debris-induced osteolysis. J Bone Miner Res. 2001;16:660-70.
23. Tsuboi H, Nampe A, Matsui Y, et al. Celecoxib prevents juxta-articular osteopenia and growth plate destruction adjacent to inflamed joints in rats with collagen-induced arthritis. Mod Rheumatol. 2007;17:115-22.
24. Okada Y, Pilbeam C, Raisz L, et al. Role of cyclooxygenase-2 in bone resorption. J UOEH. 2003;25:185-95.
25. Fujikawa Y, Quinn JM, Sabokbar A, et al. The human osteoclast precursor circulates in the monocyte fraction. Endocrinology. 1996;137:4058-60.
26. Taira H, Fujikawa Y, Kudo O, et al. Menatetrenone (vitamin K2) acts directly on circulating human osteoclast precursors. Calcif Tissue Int. 2003;73:78-85.
27. Takita C, Fujikawa Y, Itonaga I, et al. Infliximab acts directly on human osteoclast precursors and enhances osteoclast formation induced by receptor activator of nuclear factor kappaB ligand in vitro. Mod Rheumatol. 2005;15:97-103.
28. Matsuzaki K, Udagawa N, Takahashi N, et al. Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures. Biochem Biophys Res Commun. 1998;246:199-204.
29. Quinn JN, Elliott J, Gilliespie MT, et al. A combination of osteoclast differentiating factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro. Endocrinology. 1998;139:4424-7.
30. Davies NM, McLachlan AJ, Day RO, et al. Clinical pharmacokinetics and pharmacodynamics of celecoxib. Clin Pharmacokinet. 2000;38:225-42.
31. Han SY, Lee NK, Kim KH, et al. Transcriptional induction of cyclooxygenase-2 in osteoclast precursors is involved in RANKL-induced osteoclastogenesis. Blood. 2005;15:1240-5.
32. Fu JY, Masferrer JL, Seibert K, et al. The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J Biol Chem. 1990;265:16737-40.
33. Hla T, Neilson K. Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci USA. 1992;89:7384-8.
34. Stamp L, James MJ, Cleland LG. Paracrine upregulation of monocyte cyclooxygenase-2 by mediators produced by T lymphocytes: Role of interleukin 17 and interferon-γ. J Rheumatol. 2004;31:1246-54.0
35. Inoue Y, Otsuka T, Niiro H, et al. Novel regulatory mechanisms of CD40-induced prostanoid synthesis by IL-4 and IL-10 in human monocytes. J Immunol. 2004;172:2147-54.
36. Ono K, Akatsu T, Kugai N, et al. The effect of deletion of cyclooxygenase-2, prostaglandin receptor EP2, or EP4 in bone marrow cells on osteoclasts induced by mouse mammary cancer cell lines. Bone. 2003;33:798-804.